Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 14.46 CNY -1.03% Market Closed
Market Cap: 21.6B CNY
Have any thoughts about
Tasly Pharmaceutical Group Co Ltd?
Write Note

Tasly Pharmaceutical Group Co Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tasly Pharmaceutical Group Co Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Operating Expenses
-ÂĄ4.2B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Expenses
-ÂĄ6.4B
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Expenses
-ÂĄ1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Expenses
-ÂĄ16.2B
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Expenses
-ÂĄ6.5B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
-14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Expenses
-ÂĄ1.1B
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
21.6B CNY
Industry
Pharmaceuticals

In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.

Intrinsic Value
20.32 CNY
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Tasly Pharmaceutical Group Co Ltd's Operating Expenses?
Operating Expenses
-4.2B CNY

Based on the financial report for Sep 30, 2024, Tasly Pharmaceutical Group Co Ltd's Operating Expenses amounts to -4.2B CNY.

What is Tasly Pharmaceutical Group Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-6%

Over the last year, the Operating Expenses growth was 5%.

Back to Top